First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

阿替唑单抗 医学 肿瘤科 细胞毒性T细胞 内科学 癌症研究 程序性细胞死亡 肺癌 化疗 PD-L1 细胞毒性 癌症 生物 细胞凋亡 无容量 免疫疗法 体外 生物化学
作者
Leora Horn,Aaron Scott Mansfield,Aleksandra Szczęsna,Libor Havel,Maciej Jerzy Krzakowski,Maximilian Johannes Hochmair,Florian Huemer,György Losonczy,Melissa Lynne Johnson,Makoto Nishio,Martin Reck,Tony S.K. Mok,Sivuonthanh Lam,David S. Shames,Juan Liu,Beiying Ding,Ariel López-Chávez,Fairooz F. Kabbinavar,Wei Y. Lin,Alan B. Sandler
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:379 (23): 2220-2229 被引量:3729
标识
DOI:10.1056/nejmoa1809064
摘要

BACKGROUND: Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy. METHODS: We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1, or no additional clinical benefit. The two primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat population. RESULTS: A total of 201 patients were randomly assigned to the atezolizumab group, and 202 patients to the placebo group. At a median follow-up of 13.9 months, the median overall survival was 12.3 months in the atezolizumab group and 10.3 months in the placebo group (hazard ratio for death, 0.70; 95% confidence interval [CI], 0.54 to 0.91; P=0.007). The median progression-free survival was 5.2 months and 4.3 months, respectively (hazard ratio for disease progression or death, 0.77; 95% CI, 0.62 to 0.96; P=0.02). The safety profile of atezolizumab plus carboplatin and etoposide was consistent with the previously reported safety profile of the individual agents, with no new findings observed. CONCLUSIONS: The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann-La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
苯巴比妥发布了新的文献求助10
1秒前
研友_Zr4B4L完成签到 ,获得积分10
2秒前
11111完成签到,获得积分10
2秒前
kskfjs发布了新的文献求助20
3秒前
情怀的应助被科研小白采纳,获得10
3秒前
栗子砸发布了新的文献求助10
4秒前
chenyvxi完成签到 ,获得积分10
5秒前
小蘑菇的应助被小小酥采纳,获得10
5秒前
7秒前
8秒前
小七完成签到 ,获得积分10
8秒前
香蕉从寒完成签到,获得积分10
10秒前
wenhui完成签到 ,获得积分10
11秒前
乐观依云完成签到,获得积分10
12秒前
KK完成签到 ,获得积分10
12秒前
13秒前
13秒前
woo发布了新的文献求助10
13秒前
橘子完成签到,获得积分10
14秒前
李健的小迷弟的应助被graves采纳,获得10
16秒前
星空发布了新的文献求助10
16秒前
16秒前
酷波er的应助被haha采纳,获得10
16秒前
木头发布了新的文献求助10
17秒前
18秒前
111发布了新的文献求助10
20秒前
wenmu完成签到 ,获得积分10
21秒前
激动的55完成签到 ,获得积分10
21秒前
cos完成签到,获得积分10
21秒前
无敌小宝贝完成签到 ,获得积分20
21秒前
Aria_chao完成签到,获得积分10
22秒前
星空完成签到,获得积分10
22秒前
马腾龙完成签到,获得积分10
24秒前
25秒前
25秒前
舒服的幼荷完成签到,获得积分10
25秒前
zzy完成签到,获得积分10
25秒前
25秒前
Maestro_S的应助被木头采纳,获得10
27秒前
zzy发布了新的文献求助10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614